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OBJECTIVE — Arterialpulsepressureisconsideredtobeanindependentcardiovascularrisk
factor. We compared pulse pressure during an active orthostatic test in middle-aged patients
with type 1 diabetes and with type 2 diabetes and corresponding nondiabetic control subjects.
RESEARCH DESIGN AND METHODS — Forty patients with type 1 diabetes (mean
age 50 years, diabetes duration 23 years, and BMI 23.0 kg/m
2) were compared with 40 nonhy-
pertensivepatientswithtype2diabetes(respectively,50years,8years,and29.7kg/m
2).Patients
taking antihypertensive agents or with renal insufﬁciency were excluded. All patients were
evaluatedwithacontinuousnoninvasivearterialbloodpressuremonitoring(Finapres)instand-
ing (1 min), squatting (1 min), and again standing position (1 min). Patients with type 1 or type
2 diabetes were compared with two groups of 40 age-, sex- and BMI-matched healthy subjects.
RESULTS — Patients with type 1 diabetes and patients with type 2 diabetes showed signiﬁ-
cantly higher pulse pressure, heart rate, and double product of pulse pressure and heart rate
(PPHR)(type1:5,263vs.4,121mmHg/min,P0.0004;type2:5,359vs.4,321mmHg,P
0.0023) levels than corresponding control subjects. There were no signiﬁcant differences be-
tween patients with type 1 diabetes and type 2 diabetes regarding pulse pressure (59 vs. 58
mmHg), heart rate (89 vs. 88/min), and PPHR (5,263 vs. 5,359 mmHg/min).
CONCLUSIONS — Patients with type 1 diabetes have increased levels of peripheral PP, an
indirectmarkerofarterialstiffness,andPPHR,anindexofpulsatilestress,comparabletothose
of nonhypertensive patients with type 2 diabetes at similar mean age of 50 years.
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A
rterial pulse pressure, a surrogate
marker of large artery stiffness, was
shown to be an independent cardio-
vasculardisease(CVD)riskfactorinseveral
large longitudinal studies in patients with
type2diabetes(1,2).Inpatientswithtype1
diabetes of the Finnish Diabetic Nephropa-
thy (FinnDiane) study (3), higher systolic
blood pressure and an earlier decrease in
diastolicbloodpressureresultedinahigher
and more rapidly increasing pulse pressure
comparedwiththoseinnondiabeticcontrol
subjects. In the EURODIAB study (4,5),
pulsepressurewasalsoanindependentrisk
factor for CVD and total mortality in pa-
tients with type 1 patients.
Middle-aged patients with type 1 di-
abetes are characterized by a long dura-
tionofthediseaseandthereforesustained
exposure to chronic hyperglycemia, lead-
ing to accelerated progression of arterial
stiffness and increased pulse pressure (6).
In contrast, middle-aged patients with
type 2 diabetes have a much shorter du-
rationofdiabetesbuthaveotherCVDrisk
factorssuchasabdominalobesity,insulin
resistance, and metabolic syndrome,
which could accelerate arterial stiffness
(1,2). To our knowledge, no study has
compared pulse pressure in patients with
type1diabetesandinpatientswithtype2
diabetesatsimilarage.Theprimaryaimof
the present study was to investigate pul-
satile stress in patients with type 1 diabe-
tes and patients with type 2 diabetes at a
similar mean age of 50 years. Each group
of diabetic patients was compared with a
group of nondiabetic control subjects,
matched for age, sex, and BMI. Blood
pressure and pulse pressure were moni-
tored during an active postural test, the so-
calledsquattingtest,whichhasbeenshown
by our group to amplify the pulse pressure
increase according to diabetes duration in
patients with type 1 diabetes (7,8).
RESEARCH DESIGN AND
METHODS— Forty patients (20 men
and20women)withtype1diabetesand40
patients (20 men and 20 women) with type
2 diabetes were recruited among the pa-
tients followed in our department. Patients
with arterial hypertension, renal insufﬁ-
ciency,orCVDortakingmedicationsinter-
fering with vascular reactivity (including
any type of antihypertensive agents) were
excluded from the study. All patients with
type 1 diabetes received intensiﬁed insulin
therapy with multiple daily insulin injec-
tions (n36) or continuous subcutaneous
insulin infusion via a portable pump (n 
4). Patients with type 2 diabetes received
various types of oral glucose-lowering ther-
apies (metformin alone, sulfonylurea alone,
or metformin-sulfonylurea combination)
(n  25) or insulin alone (n  5) or com-
bined with metformin (n  10). Two
groupsofhealthysubjectswereusedascon-
trol subjects and matched for BMI with ei-
ther type 1 diabetic patients or type 2
diabetic patients (Table 1). The study was
accepted by the ethics committee of our
institution.
Orthostatic test
The squatting test (successively 1 min
standing, 1 min squatting, and 1 min
standing) is an original active orthostatic
maneuver that leads to the most impor-
tant and fast variations of the hydrostatic
levelwithposture(9).Squattingproduces
a prompt increase in cardiac output and
arterial blood pressure, essentially attrib-
uted to augmented venous return from
compression of leg veins. These changes
result in a signiﬁcant increase in mean ar-
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(7,8), which is accompanied by an imme-
diate decrease in heart rate and forearm
vascular resistance, probably due to acti-
vation of cardiopulmonary and arterial
baroreﬂexes, implicating the autonomic
nervous system. Later on, the active transi-
tion from squatting to standing results in a
profoundinitialbloodpressuredecreasein-
ducing a reﬂex tachycardia, which can be
used to detect diabetic cardiac autonomic
neuropathy (CAN) (10,11) and assess
baroreﬂex sensitivity (12).
Measurements
Changes in systolic blood pressure (SBP),
diastolic blood pressure (DBP), and heart
rate were measured continuously with a
Finapres instrument (Ohmeda) that al-
lows careful study of cardiovascular re-
ﬂexes, especially during an orthostatic
maneuver (13). The Finapres is based on
servoplethysmomanometry, using the
volume clamp technique at the ﬁnger
level. A good concordance was reported
between Finapres blood pressure mea-
surements and direct intra-arterial mea-
surements (13). Pulse pressure, i.e., SBP
minus DBP, was automatically calculated
throughout the test. Mean arterial blood
pressure (MBP) was calculated by the for-
mula(SBP2DBP)/3.Toquantifythe
relative magnitude of the pulsatile to mean
arterypressure(“pulsatilityindex”),wenor-
malized the pulse pressure to the MBP and
referred to this value as fractional pulse
pressure (14). “Pulsatile stress” was deﬁned
asthedoubleproductofpulsepressureand
heart rate (PPHR)); it has been shown to
be largely regulated by arterial stiffness and
by sympathetic nerve activity and to be as-
sociated with a higher risk of (micro)albu-
minuria (15). We also calculated the
SBPHR double product, an index of car-
diac load that has been shown to be associ-
ated with an increased CVD risk (16). For
each variable or parameter, mean levels
were calculated for each subject during the
whole period of the test, during the initial
standing position, and during the squatting
position, after exclusion of the initial transi-
tion phase, as described previously (7,8).
During the transition from squatting to
standing, there is an abrupt drop in blood
pressure associated with a reﬂex tachycar-
dia, which is followed by a rapid return to
baseline values of both parameters (blood
pressure increase and heart rate decrease).
The mirror changes in heart rate and SBP
allow the calculation of a baroreﬂex gain by
plotting the pulse intervals (R-R) against
SBP values, and the slope of this relation
represents the baroreﬂex sensitivity (17).
We also calculated both a vagal index (ratio
between the baseline cardiac R-R interval
and the longest R-R interval in the ﬁrst 15 s
of squatting [SqTv]) and a sympathetic in-
dex (ratio between the baseline cardiac R-R
interval and the shortest R-R interval in the
ﬁrst 10–20 s of standing after squatting
[SqTs]), as described previously (10,11).
These indexes, based on heart rate reduc-
tionduringsquattingandreﬂextachycardia
during standing, were considered as mark-
ers of CAN: a higher SqtV value indicates a
parasympathetic neuropathy, whereas a
lower SqTs is an indicator of sympathetic
neuropathy (10–12).
Concomitant A1C levels (normal val-
ues 4–6%) were measured to assess re-
cent blood glucose control in diabetic
patients;foreachpatient,thecorrespond-
ing A1C mean level corresponded to the
average of one to three measurements.
Lipid proﬁles were also collected in dia-
betic patients and the prevalence of the
metabolic syndrome (National Choles-
terolEducationProgramAdultTreatment
Panel III criteria) was calculated in pa-
tients with type 1 diabetes and in patients
with type 2 diabetes.
Statistical analysis
The required sample size to have an 80%
chance of detecting as signiﬁcant (at the
two-sided5%level)10mmHgdifferencein
pulse pressure between two different sub-
groups, with an assumed SD of pulse pres-
sure of 14 mmHg, was 32 individuals. A
difference of 10 mmHg was chosen as clin-
ically signiﬁcant because it has been shown
tobeassociatedwithincreasedcardiovascu-
lar mortality in type 2 diabetes (1) and total
mortality in the large EURODIAB cohort of
patients with type 1 diabetes (5). Between-
group differences were analyzed using un-
pairedttests.Therelationshipbetweentwo
variables, i.e., between pulsatile stress and
baroreﬂex gain as a marker of CAN, was
assessed with the Spearman correlation co-
efﬁcient. Results are expressed as mean 
SD values for all continuous variables. P 
0.05 was considered signiﬁcant.
Table1—Characteristicsofmiddle-ageddiabeticpatientswithtype1diabetes,patientswithtype2diabetes,nondiabeticleancontrolsubjects,
and nondiabetic overweight/obese control subjects and average values recorded during the whole 3-min squatting test
T1DM LC T2DM OC
P value
T1DM
vs. LC
T2DM
vs. OC
n (men/women) 20/20 20/20 20/20 20/20
Age (years) 50  65 0  65 0  65 0  6 0.8888 0.8971
Diabetes duration (years) 23  11 — 8  7 — NA NA
BMI (kg/m
2) 23.0  2.0 22.2  1.6 29.7  3.7 28.6  2.7 0.0642 0.1288
A1C (%) 8.4  1.3 — 7.8  1.6 — NA NA
Mean blood pressure (mmHg) 84  13 85  12 88  13 86  12 0.9719 0.5991
SBP (mmHg) 126  21 120  21 128  20 122  18 0.1649 0.1087
DBP (mmHg) 66  11 68  10 70  13 70  10 0.6195 0.1662
Pulse pressure (mmHg) 59  13 52  15 58  16 52  13 0.0160 0.0451
Pulse pressure-to-MBP ratio 0.703  0.121 0.610  0.139 0.677  0.245 0.603  0.152 0.0020 0.1082
Heart rate (bpm) 88  13 80  99 1  10 84  13 0.0029 0.0029
PPHR product (mmHg   min
1) 5,263  1,563 4,121  1,120 5,359  1,641 4,321  1,277 0.0004 0.0023
SBPHR product (mmHg   min
1) 11,120  2,947 9,593  1,771 12,082  2,521 10,195  2,291 0.0039 0.0008
Data are means  SD. LC, nondiabetic lean control subjects; NA, not applicable; OC, nondiabetic overweight/obese control subjects; T1DM, patients with type 1
diabetes, T2DM, patients with type 2 diabetes.
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Patients with type 1 diabetes versus
nondiabetic lean subjects
Compared with control subjects, patients
with type 1 diabetes had similar MBP but
werecharacterizedthroughoutthetestby
signiﬁcantly higher pulse pressure, heart
rate, pulse pressure/MBP, PPHR, and
SBPHR levels (Fig. 1A, Table 1). When
squatting was compared with the initial
standing position, a trend for higher in-
creases in pulse pressure, PP/MBP, and
PPHR was observed in patients with
type 1 diabetes than in control subjects,
with a signiﬁcantly higher increase in
SBPHR (Table 2). The baroreﬂex gain
calculated during the transition from
squatting to standing was markedly de-
creased in patients with type 1 diabetes
compared with that in control subjects.
SqTv and SqTs indexes were also signiﬁ-
cantly different in patients with type 1 di-
abetes compared with those in lean
Figure 1—Changes in MBP, pulse pressure (PP), and heart rate (HR) during a posture test (1 min standing, 1 min squatting [gray zone], 1 min
standing). A: 40 patients with type 1 diabetes (E) versus 40 nondiabetic (F) subjects, matched for age, sex, and BMI. B: 40 patients with type 2
diabetes (‚) versus 40 nondiabetic (Œ) subjects matched for age, sex, and BMI. C: 40 patients with type 1 diabetes (E) versus 40 patients with type
2 diabetes (‚) subjects, matched for age and sex.
Pulsatile stress in diabetes
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signiﬁcant inverse correlation between
pulsatile stress (PPHR) and baroreﬂex
gain in patients with type 1 diabetes (r 
0.383; P  0.023) but not in lean con-
trol subjects (r  0.178; NS).
Patients with type 2 diabetes versus
nondiabetic overweight/obese
patients
Compared with overweight/obese nondi-
abetic control subjects, patients with type
2diabeteshadsimilarMBP(hypertension
was considered as an exclusion criterion
in the present study). However, they
showed higher pulse pressure, heart rate,
pulse pressure-to-MBP ratio, PPHR,
and SBPHR levels throughout the test
(Fig.1B,Table1).Increasesinpulsepres-
sure, pulse pressure-to-MBP ratio,
PPHR, and SBPHR when moving
from standing to squatting were not sig-
niﬁcantly different in patients with type 2
diabetes and in overweight/obese nondi-
abetic control subjects (Table 2). The
baroreﬂex gain was signiﬁcantly de-
creased in patients with type 2 diabetes
compared with that in control subjects.
The SqTs index (reﬂecting postsquatting
tachycardia) but not the SqTv index (a
marker of bradycardia during squatting)
was signiﬁcantly lower in patients with
type 2 diabetes than in overweight/obese
nondiabetic control subjects (Table 2).
Therewasahighlysigniﬁcantinversecor-
relation between pulsatile stress and
baroreﬂex gain in patients with type 2 di-
abetes (r  0.719; P  0.0001) but not
in overweight/obese control subjects (r 
0.272; NS). No signiﬁcant differences
in pulsatile markers and CAN indexes
were noticed between the patients with
type 2 diabetes treated with insulin and
those not treated with insulin.
Patients with type 1 diabetes versus
patients with type 2 diabetes
Onaverage,MBP,pulsepressure,heartrate,
pulse pressure-to-MBP ratio, PPHR, and
SBPHR levels were comparable in mid-
dle-aged patients with type 1 and type 2
diabetes (Fig. 1C, Table 1). The transition
from standing to squatting resulted in
similar increases in MBP, pulse pressure,
pulse pressure-to-MBP ratio, PPHR,
and SBPHR in the two groups of dia-
betic patients (Table 2). Careful analysis
of the two pulse pressure curves showed
different kinetics in pulse pressure in-
creases, with a second phase increase in
pulse pressure in patients with type 1 di-
abetes that was not observed in patients
with type 2 diabetes; however, the be-
tween-group difference during the sec-
ond part of squatting did not reach
statistical signiﬁcance (Fig. 1C). The
baroreﬂex gain was similar in patients
with type 1 and type 2 diabetes. Accord-
ingly, SqTv and SqTs indexes were not
signiﬁcantlydifferentbetweenthetwodi-
abeticgroups(Table2).Patientswithtype
1 diabetes had a much longer known dis-
easeduration(23vs.8years;P0.0001)
butamuchlowerprevalenceofmetabolic
syndrome (3% vs. 42%; P  0.01) than
patients with type 2 diabetes.
Overweight/obese versus lean
subjects without diabetes
Onaverage,MBP,pulsepressure,heartrate,
pulse pressure-to-MBP ratio, PPHR, and
SBPHRlevelswerecomparableinobese
and lean nondiabetic individuals in the
present study (Table 1). The postural
change from standing to squatting re-
sulted in similar increases in MBP, pulse
pressure, pulse pressure-to-MBP ratio,
andPPHRinoverweight/obeseandlean
subjects, with only a trend for a higher
increase in SBPHR (963  1,178
vs.  601  698 mmHg   min
1; P 
0.0991) in presence of obesity (Table 2).
The baroreﬂex gain was signiﬁcantly
lower in overweight/obese subjects than
in lean individuals (2.97  2.18 vs.
4.11  2.26 mmHg   min
1; P 
0.0332), even in absence of diabetes. The
SqTv index was higher in obese subjects
than in lean control subjects (P 
0.0011), whereas the SqTs index was al-
most similar in the two nondiabetic
groups (Table 2).
CONCLUSIONS — The main ﬁnd-
ings of the present study are 1) higher
pulsepressure,pulsepressure-to-MBPra-
tio, PPHR, and SBPHR levels in mid-
dle-aged patients with type 1 diabetes
compared with those in lean control sub-
jects, in agreement with higher pulsatile
stress and cardiac workload in patients
with long-standing type 1 diabetes, 2)
similarly, higher pulse pressure, pulse
pressure-to-MBP ratio, PPHR, and
SBPHR levels in middle-aged nonhy-
Table 2—Changes occurring during the transition from the initial standing position to the squatting position in middle-aged diabetic patients
with type 1 diabetes, patients with type 2 diabetes, nondiabetic lean control subjects, and nondiabetic overweight/obese control subjects
T1DM LC T2DM OC
P value
T1DM
vs. LC
T2DM
vs. OC
N 40 40 40 40
 MBP (mmHg) 8  75  41 0  97  8 0.0185 0.0875
 SBP (mmHg) 13  11 8  71 4  14 9  11 0.0101 0.0754
 DBP (mmHg) 3  51  46  73  7 0.0141 0.1391
 Pulse pressure (mmHg) 10  87  68  11 6  7 0.0705 0.1662
 Pulse pressure-to-MBP ratio 0.127  0.110 0.087  0.074 0.095  0.133 0.065  0.082 0.0593 0.2371
 Heart rate (/min) 6  7 6  6 6  7 2  7 0.7449 0.0123
 PPHR product (mmHg   min
1) 557  935 276  532 449  942 404  743 0.1029 0.8132
 SBPHR product (mmHg   min
1) 1,136  1,270 601  698 1,236  1,440 963  1,178 0.0227 0.3611
Baroreﬂex gain (mmHg   min
1) 2.20  1.73 4.11  2.26 2.05  1.31 2.97  2.18 0.0002 0.0351
SqTv index 0.88  0.08 0.81  0.13 0.90  0.07 0.89  0.09 0.0059 0.7553
SqTs index 1.13  0.09 1.20  0.11 1.13  0.07 1.21  0.10 0.0046 0.0004
DataaremeansSD.MeanvaluesofbaroreﬂexgainaswellasSqTvandSqTsindicesofcardiacautonomicneuropathyarealsopresentedforthefourgroups.There
were 20 men and 20 women in each group. LC, nondiabetic lean control subjects; OC, nondiabetic overweight/obese control subjects; T1DM, patients with type 1
diabetes; T2DM, patients with type 2 diabetes.
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comparedwiththoseinoverweight/obese
nondiabetic control subjects, 3) the ab-
sence of signiﬁcant differences in pulse
pressure, pulsatile index, pulsatile stress,
and double product between patients
with type 1 diabetes and with type 2 dia-
betes matched for age (50 years on aver-
age); and 4) indexes of CAN as shown by
lower baroreﬂex gain and altered SqT in-
dexes during squatting in both patients
with type 1 diabetes and type 2 diabetes
compared with those in nondiabetic con-
trol subjects. Therefore, middle-aged pa-
tients with type 1 diabetes or with type 2
diabetes are exposed to comparable pul-
satile stress, a known cardiovascular and
renalriskmarker(1–5,15,16).Inpatients
with type 1 diabetes, the negative inﬂu-
ence of a much longer diabetes duration
(23 years on average in the present study)
might be at least partially compensated
forbythepositiveinﬂuenceoflowerBMI,
less insulin resistance, and a much lower
prevalence of metabolic syndrome com-
pared with those for patients with type 2
diabetes. On the contrary, middle-aged
patients with type 2 diabetes are exposed
to high pulsatile stress despite a shorter
known duration of diabetes (8 years on
average in our population), presumably
because of the presence of other concom-
itant cardiovascular risk factors (even if
hypertension were excluded in the
present study), as shown by a much
higher prevalence of metabolic syndrome
compared with that for patients with type
1 diabetes.
The observation of higher pulse pres-
surelevelsinpatientswithtype1diabetes
comparedwithcontrolsubjectsintheage
range 40–60 years is in agreement with
previous studies from our group, demon-
strating an earlier pulse pressure increase
withageinthispopulation(7,8)andwith
the observational data of the large cross-
sectional, case-control FinnDiane study
(3). Because pulse pressure is considered
an indirect marker of arterial stiffness,
these higher pulse pressure results are in
agreement with accelerated vascular ag-
ing in the population with type 1 diabetes
(6), especially patients with chronic poor
glucose control (18). In the FinnDiane
study, the ambient level of glucose was
not associated with increased pulse pres-
sure, but the time of exposure to hyper-
glycemia seemed to play a fundamental
role in the process of premature arterial
stiffening in patients with type 1 diabetes
(3). In the EURODIAB Prospective Com-
plications Study, pulse pressure was sig-
niﬁcantly associated with all-cause
mortality and a mean 12 mmHg higher
pulse pressure was observed in patients
with type 1 diabetes who died compared
with that of those who survived (5).
Decreased baroreﬂex gain was ob-
served in our patients with type 1 diabe-
tes, reﬂecting the presence of CAN after
20 years of diabetes (19). This result
was conﬁrmed by altered SqTs and SqTv
indexesduringthesquattingtest,markers
of parasympathetic and sympathetic dys-
function, respectively (10). CAN exposes
diabeticpatientstoanincreasedmortality
risk (19). There may be some connection
between pulse pressure and CAN (8), be-
tween aortic stiffness and CAN (20), and
between arterial stiffness, cardiovagal
baroreﬂex sensitivity, and postural blood
pressure changes (21). Increased SBP was
identiﬁed as a factor associated with an
increased risk of developing CAN in the
cohort of patients with type 1 diabetes of
the EURODIAB Prospective Complica-
tions study (22). The pathophysiological
mechanism linking CAN to arterial stiff-
ness in patients with type 1 diabetes re-
mains unknown, but this association
persisted after adjustment for potential
confounders such as baseline A1C, HDL
cholesterol, and smoking history (23). In
the present study, we found a signiﬁcant
relationship between pulsatile stress and
baroreﬂex gain as a marker of CAN in pa-
tients with type 1 diabetes. In patients
with type 2 diabetes, markers of CAN are
also present (11), although less marked
than in patients with prolonged type 1
diabetes (7). The relationship between
pulse pressure and CAN is less well
known in patients with type 2 diabetes
even if associations between autonomic
neuropathy, vascular dysfunction, and
hyperinsulinemia have been demon-
strated (24). Interestingly, a remarkable
signiﬁcant inverse correlation was noted
between pulsatile stress and baroreﬂex
gain in the group of patients with type 2
diabetes in our study. Several mecha-
nisms may underlie the association be-
tween arterial stiffness and impaired
cardiovagal baroreﬂex sensitivity. The
stiffness of the carotid arteries and the
aorta,wherethearterialbaroreceptorsare
located, may affect the stretch-sensitive
receptors and hence baroreﬂex sensitiv-
ity. In addition to structural vascular
changes, functional mechanisms associ-
ated with endothelial dysfunction may
also contribute to the impairment of
baroreﬂexsensitivityassociatedwitharte-
rial stiffness (21).
Patients with type 2 diabetes also
showedincreasedpulsepressure,pulsatility
index, and pulsatile stress compared with
those for overweight/obese nondiabetic in-
dividuals matched for BMI, age, and sex.
This result was observed despite the ab-
sence of hypertension and a much shorter
durationofdiabetescomparedwiththosein
the population with type 1 diabetes ana-
lyzedinthepresentstudy.Itiswellknown,
however,thattype2diabetesremainssilent
during an average of 10 years before diag-
nosis and initiation of treatment in most
cases. Thus, selected patients may have a
longer duration of type 2 diabetes than the
average8-yearknowndurationnotedinthe
present population. To avoid the potential
biasofhypertensionandtheinterferencesof
antihypertensive agents, we deliberately se-
lected type 2 diabetic patients without hy-
pertension. Despite normal MBP, middle-
aged patients with type 2 diabetes had
higher pulse pressure and pulsatile stress
and higher SBPHR, two CVD risk mark-
ers (16). Increased pulse pressure levels
havebeenrepeatedlydemonstratedinlarge
longitudinal studies in patients with type 2
diabetes and shown to be associated with a
higher incidence of cardiovascular events
(1,2).
Some limitations of the present study
should be discussed. Several studies have
demonstrated that absolute brachial and
ﬁnger pulse pressure measurements are
not identical with larger differences in
SBP. However, the differences were gen-
erally small and not considered of clinical
relevance (13). Furthermore, some stud-
ies have shown a good concordance be-
tween periphery (ﬁnger, as in the present
study) and central (aortic, now recog-
nized as the most important risk factor)
blood pressure measurements (25). Nev-
ertheless, pulse pressure measured at the
ﬁnger site may not necessarily reﬂect cen-
tral pulse pressure because of the ampli-
ﬁcation phenomenon. Second, glucose
control of patients with type 1 diabetes
evaluated in the present study was far
from optimal, despite intensiﬁed insulin
therapy. Therefore, our results could not
necessarily be extrapolated to patients
with near normoglycemia for many years
because chronic hyperglycemia seems to
play a major role in accelerating arterial
stiffness (18). Third, patients with type 2
diabetes selected in the present study did
not have hypertension. Therefore, the
similar results in markers of pulsatile
stress in middle-aged patients with type 1
and type 2 diabetes should be interpreted
in this context. We cannot exclude the
Pulsatile stress in diabetes
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with type 2 diabetes and hypertension
may be exposed to higher vascular stress
thanleannormotensivepatientswithtype1
diabetes at the same age. This would cer-
tainlybethecaseforSBPHRbutmayalso
be true for the various pulsatility markers.
Fourth, very few patients had positive mi-
croalbuminuria in the two diabetic cohorts
analyzed in the present study, because we
excluded patients with hypertension or
those taking antihypertensive agents.
Therefore, we were not in a position to
study the possible relationship between
pulsatile stress and early renal alterations as
shown in previous studies (15).
In summary, middle-aged patients
with a long duration of type 1 diabetes
have similarly increased pulsatile stress
compared with age-matched patients
with type 2 diabetes characterized by a
shorter duration of the disease, but the
presence of other vascular risk factors
such as obesity and insulin resistance and
no hypertension. In addition, both dia-
betic groups have markers of CAN with a
reduced baroreﬂex gain compared with
nondiabetic control subjects. The combi-
nationoftheseriskfactorsmaycontribute
toincreasetheCVDriskintype1diabetic
patients with a long exposure to chronic
hyperglycemia in a fashion similar to that
of patients with type 2 diabetes whose
high CVD risk is well known.
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